Solici

On #RareDiseaseDay, Associate Consultant Sarah Laverty, PhD, highlights the potential of Alyftrek, Vertex Pharmaceuticals' 5th CFTR modulator. With its once-daily dosing and non-inferiority to Trikafta, Alyftrek offers a significant opportunity to expand patient eligibility and potentially improve patient compliance. This could not only transform patient care for those ineligible for other CFTR modulators but also drive an estimated additional $55 million in revenue for Vertex in the US alone. As Sarah discusses, while CFTR modulators like Alyftrek are a breakthrough, gene therapies may remain crucial for achieving a true cure. #CysticFibrosis #Alyftrek #CFTRModulators #Vertex #GeneTherapy #RareDiseases

Looking to Elevate Your Healthcare Strategy? The future of healthcare depends on real-time, actionable data. Solici provides the monitoring tools you need to stay ahead, improve outcomes, and increase operational efficiency. 💡 Are you ready to make smarter, faster decisions? Learn more about our customised monitoring solutions. 🔗 https://lnkd.in/eZheFDS9 #DataDrivenDecisions #MonitoringServices

Meet our Consultants, Cloe Ferrando and Philip Myers at CONEXEN later today! #Conexen2025

Following the success of the Medicare Drug Price Negotiations, The Department of Health and Human Services (HHS) has announced plans to begin negotiating prices for 15 additional drugs, with the aim of lowering costs. In accordance with the Inflation Reduction Act, negotiations will be carried out throughout 2025, and negotiated prices will come into place in 2027. In our post below, Solici consultants consider how manufacturers might strategically respond to the new drug selections 👇

A brilliant opportunity for an experienced research professional to join the new Cambridge Healthcare Research Centre of Excellence! Applications are open now 👇

A fantastic opportunity to join Cambridge Healthcare Research in the new Birmingham office!

The 2025 J.P. Morgan Healthcare Conference lived up to its deal-making reputation with the resurgence of multi-billion-dollar buyout activity. Solici’s top picks for #JPM25 feature some mega-M&A deals that have set the tone for the year ahead.   Johnson & Johnson kicked things off to a strong start with plans to acquire Intra-Cellular Therapies for $14.6 billion. The deal includes #Caplyta, approved in the US for bipolar disorder and schizophrenia and currently under FDA review for depression. With a neuropsych powerhouse like J&J backing Caplyta, could an EMA approval be on the horizon? Or will Europe's heavily genericised market and pricing pressures keep J&J from bringing its newest asset across the Atlantic?   Eli Lilly and Company jumped in with plans to acquire Scorpion Therapeutics' PI3Kα pipeline for up to $2.5 billion. This strategic move strengthens Lilly’s oncology pipeline and positions it to take on industry leaders Roche and Novartis in the breast cancer space.   Not to be forgotten are GSK, set to acquire IDRx for up to $1.15 billion, enhancing GSK’s growing GI cancer portfolio, AbbVie, licensing new blood cancer drug candidate from Simcere with a deal valued at up to $1.06 billion, and MSD acquiring Harpoon Therapeutics to bolster its oncology pipeline.   Finally, Synaffix BV partnered with Boehringer Ingelheim in a $1.3 billion antibody drug conjugates (ADC) tech pact, while Roche made waves with its $780 million ADC collaboration with Chugai Pharmaceutical Co., Ltd.. Clearly, it’s time to practice your ADCs, and the big boys are showing that innovation in this space is as much about partnerships as pipelines.   The #JPMHC25 M&A surge is largely attributed to expectations of a more lenient antitrust environment under the incoming #Trump administration, encouraging companies to consolidate and expand their portfolios, particularly in oncology and rare diseases. Could JPM2025 be just the beginning of a new era pharma deal making?   #JPMHC25 #healthcare #pharma

2025 is in full swing and we are looking forward to the year ahead and the great things we will achieve together! We asked a variety of people across our teams what they like the most about working at CHR - watch this short video to hear what they had to say. #community #collaboration #inspiration #marketresearch #competitiveintelligence #2025

As we prepare to log off for 2024, we want to say thank you to all our followers, clients, and most importantly our team for supporting us throughout the year. We hope you have a very Merry [CHR]istmas, and a Happy New Year! 🎄

In 2024, we continued our focus on sustainability and community, and officially rank in the top 35% of sustainable companies by EcoVadis! We have improved our EcoVadis Bronze status by reducing our carbon emissions, and offsetting those we can't. Thank you to our team for all the work taking us a step closer to our net zero goal. Our brilliant CHR For Society team have also been able to raise £3,640 in charity donations. In 2025, we will be continuing to work closely with charities, and continue contributing to the greater good. See our webpage below to find out more about the great work from CHR For Society: https://lnkd.in/e4y6XGJ4 #SustainabilityInPharma #SustainableBusiness